IPD spinout Neoleukin merges with Aquinox for NASDAQ listing

Neoleukin thinks its merger with Aquinox announced Tuesday will enable the de novo protein design newco to submit an IND for its IL-2 mimetic and announce additional preclinical programs by the end of 2020.

The combined company, Neoleukin Therapeutics Inc. (NASDAQ:NLTX), will be capitalized with about $65 million. About 61.4% of the combined company will be held by Aquinox's shareholders, and the balance by Neoleukin's...